Valuation: Genovis AB

Market Cap 1.27B 127M 112M 106M 95.59M 180M 12.17B 182M 488M 6.22B 477M 466M 19.94B P/E 2026 *
59.6x
P/E 2027 * 37.6x
Enterprise Value 1.16B 116M 102M 96.61M 87.22M 164M 11.1B 167M 445M 5.68B 435M 425M 18.2B EV / Sales 2026 *
7.85x
EV / Sales 2027 * 6.05x
Free-Float
92.6%
Yield 2026 *
-
Yield 2027 * -
1 day+1.19%
1 week-1.47%
1 month-15.21%
3 months-4.67%
6 months+3.99%
Current year-11.62%
1 week 17.96
Extreme 17.96
19.06
1 month 17.96
Extreme 17.96
22.05
Current year 15.64
Extreme 15.64
23.65
1 year 15.64
Extreme 15.64
24.5
3 years 15.64
Extreme 15.64
53.9
5 years 15.64
Extreme 15.64
90
10 years 2.18
Extreme 2.18
90
Manager TitleAgeSince
Chief Executive Officer 55 2015-05-04
Director of Finance/CFO 42 2026-07-31
Chief Tech/Sci/R&D Officer 42 2016-12-31
Director TitleAgeSince
Director/Board Member 77 2013-12-31
Director/Board Member 65 2018-12-31
Chairman 74 2020-05-04
Date Insider Type Main position Quantity % Market Cap. Importance
5/15/26 Buy 4,146 0.0063%
2/24/26 Buy

Chief Financial Officer

3,137 0.0047%
2/24/26 Buy

Chief Financial Officer

2,470 0.0037%
Change 5-day change 1-year change 3-year change Capi.($)
+1.19%-1.47%-19.23%-59.53% 125M
-2.10%-4.50%-26.21%+2.04% 175B
-0.92%-3.37%-9.40%+10.12% 111B
-0.90%+0.73%-25.50%+0.78% 107B
+0.69%-2.90%-47.25%-11.84% 75.31B
-2.39%-3.85%-3.93%+66.83% 58.7B
-1.63%-1.93%-4.37%-30.76% 49.57B
+1.95%+3.93%+16.86%+58.64% 49.27B
-2.11%+0.03%-18.27%+19.42% 42.02B
-0.40%-1.64%+28.24%-7.51% 32.69B
Average -0.23%-1.85%-10.90%+4.82% 70.07B
Weighted average by Cap. +0.02%-2.20%-16.23%+9.31%

Financials

2026 *2027 *
Net sales 147M 14.75M 12.99M 12.31M 11.11M 20.94M 1.41B 21.21M 56.67M 723M 55.39M 54.18M 2.32B 185M 18.58M 16.36M 15.5M 13.99M 26.37M 1.78B 26.71M 71.37M 911M 69.76M 68.24M 2.92B
Net income 15.7M 1.57M 1.38M 1.31M 1.18M 2.23M 151M 2.26M 6.04M 77.09M 5.91M 5.78M 247M 33.6M 3.37M 2.96M 2.81M 2.54M 4.78M 323M 4.84M 12.93M 165M 12.64M 12.36M 529M
Net Debt -111M -11.12M -9.79M -9.28M -8.38M -15.79M -1.07B -15.99M -42.72M -545M -41.75M -40.84M -1.75B -145M -14.53M -12.79M -12.12M -10.94M -20.62M -1.39B -20.89M -55.8M -712M -54.54M -53.35M -2.28B
Logo Genovis AB
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Employees
42
Date Price Change Volume
26-09-30 SEK 18.78 +1.19% 225,958
26-09-29 SEK 18.56 +1.42% 2,175,314
26-09-28 SEK 18.30 -3.58% 134,205
26-09-25 SEK 18.98 +2.59% 216,048
26-09-24 SEK 18.50 -2.94% 91,865
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
18.78SEK
Average target price
33.00SEK
Spread / Average Target
+75.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENO Stock